Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Rohit K Raj
 -- 1477 2023-12-04 14:06:09 |
2 format change
Peter Tang
Meta information modification 1477 2023-12-05 02:31:58 |

Video Upload Options

Do you have a full video?
Send video materials Upload full video

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Raj, R.K.; Upadhyay, R.; Wang, S.; Singer, E.A.; Dason, S. Stereotactic Ablative Radiotherapy in Renal Cell Carcinoma Management. Encyclopedia. Available online: https://encyclopedia.pub/entry/52332 (accessed on 29 July 2024).
Raj RK, Upadhyay R, Wang S, Singer EA, Dason S. Stereotactic Ablative Radiotherapy in Renal Cell Carcinoma Management. Encyclopedia. Available at: https://encyclopedia.pub/entry/52332. Accessed July 29, 2024.
Raj, Rohit K., Rituraj Upadhyay, Shang-Jui Wang, Eric A. Singer, Shawn Dason. "Stereotactic Ablative Radiotherapy in Renal Cell Carcinoma Management" Encyclopedia, https://encyclopedia.pub/entry/52332 (accessed July 29, 2024).
Raj, R.K., Upadhyay, R., Wang, S., Singer, E.A., & Dason, S. (2023, December 04). Stereotactic Ablative Radiotherapy in Renal Cell Carcinoma Management. In Encyclopedia. https://encyclopedia.pub/entry/52332
Raj, Rohit K., et al. "Stereotactic Ablative Radiotherapy in Renal Cell Carcinoma Management." Encyclopedia. Web. 04 December, 2023.
Stereotactic Ablative Radiotherapy in Renal Cell Carcinoma Management
Edit
This entry is adapted from the peer-reviewed paper 10.3390/curroncol30120749

Stereotactic ablative radiotherapy (SABR) has challenged the conventional wisdom surrounding the radioresistance of renal cell carcinoma (RCC). There has been a significant accumulation of clinical data to support the safety and efficacy of SABR in RCC.

stereotactic ablative radiotherapy (SABR) stereotactic body radiotherapy (SBRT) radiation renal cell carcinoma oligometastasis oligoprogression

1. Introduction

Kidney cancers are amongst the top 10 cancers in the United States, with an estimated incidence of 81,000 cases and 14,890 attributable deaths in 2023 [1]. Malignant neoplasms of the kidney are complex, with several histologic types and distinct disease processes with variable clinical outcomes, the most prevalent of which is renal cell carcinoma (RCC), accounting for 80–85% of primary renal neoplasms [2]. Major subtypes of RCC include clear-cell (75–85%), papillary (10–15%), and chromophobe (5–10%) tumors. Other histological types of renal neoplasms are oncocytoma and angiomyolipoma (3–5%). At diagnosis, over one-fourth of patients present with regional and/or distant metastatic disease, and over half of patients eventually develop metastatic disease [3][4]. Overall survival across several prior studies ranges from 6 to 12 months in these patients with metastatic RCC (mRCC). While surgery remains the standard-of-care treatment modality for patients with localized RCCs, systemic therapy is the mainstay of treatment for mRCC. Historically, systemic therapies were limited to cytokine therapies, but more recently, several newer options have emerged, including immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs) [5][6][7].
In the context of management of localized, locally advanced, and metastatic RCC, stereotactic ablative radiotherapy (SABR) has emerged as another promising technique. Historically, RCC was considered to be a relatively radioresistant tumor, especially when treated with conventional fractionation utilizing a dose of <5 Gy per fraction. Radio-resistance to conventionally fractionated RT was demonstrated by Deschavanne and Fertil using cell survival curves from in vitro studies [8]. However, more advanced radiation techniques have allowed the delivery of a higher dose per fraction to renal tumors safely, which results in more effective cell killing, as demonstrated by several recent studies in vitro as well as in vivo [9][10]. Although the underlying radiobiological phenomenon responsible for this effect is poorly understood, several hypotheses include alternate mechanisms of cell killing induced by SABR (vs. conventional RT) rather than mitotic catastrophe from DNA damage, including ceramide pathway cell killing, apoptosis, and vascular endothelial damage [11][12][13]. Another plausible explanation of the radiation response seen with SABR involves the immunostimulatory effects, especially in combination with immunotherapy [14]. Chow et al. evaluated the pathology specimens of patients with primary RCC treated with single-fraction SABR to a dose of 15 Gy followed by nephrectomy four weeks later, and observed broad transcriptional immune activation and clonality of immune cells within the tumor microenvironment [15].
SABR is generally defined as a radiotherapy technique in which high doses of radiation (>5–8 Gy per fraction) are administered to the target in 1–5 fractions with a high degree of anatomic accuracy [16]. Recent clinical studies have evaluated SABR for both primary and mRCC and have shown the safety as well as efficacy of this approach, with local control (LC) rates of 90–98% [17][18][19] and grade-3 toxicities attributable to SABR of less than 5% [20].
Current North American and European society guidelines recommend SABR as a subsequent line of local therapy for unresectable or medically inoperable primary RCC, or for the local treatment of metastatic sites in select patients with oligometastatic (OM) RCC or oligoprogression [21].

2. Primary Localized RCC

Most patients with localized RCC present with a renal mass noted incidentally on imaging for another indication [22]. Local symptoms of RCC include flank discomfort and hematuria. Patients with RCC are typically staged with imaging of the chest, abdomen, and pelvis [23]. Bone and brain metastases are uncommon in the absence of symptoms or lab abnormalities.
Management of the small renal mass (≤4 cm) is highly individualized [23]. Historically, most patients with a small renal mass were managed with surgical resection. A number of trends have emerged in the past decade to limit the morbidity of small renal mass management:
  • Renal mass biopsy. There is a high rate (31%) of benign pathology in resected renal masses [24]. An effort to reduce the morbidity of resecting benign renal masses has prompted increasing use of renal mass biopsy in patients with a small renal mass. A renal mass biopsy is diagnostic in 90% of small renal masses [25]. Utilization of biopsy prior to surgical resection is highly variable—it is likely most essential when a diagnosis other than renal cell carcinoma is suspected or biopsy results would impact the decision to proceed with treatment. A young patient unwilling to accept the uncertainties of a biopsy or a comorbid patient who would undergo active surveillance regardless of biopsy are good indications to avoid a biopsy [23]. Additional imaging with 99 mTc-sestamibi SPECT/CT [26] and 89Zr-DFO-girentuximab [27] are likely to become reasonable adjuncts to biopsy in the near future.
  • Active surveillance is also increasingly utilized for small renal masses. Intermediate-term outcomes with this approach are excellent. The metastatic rate is generally low (<1–2%) in well-selected patients [28]. The DISSRM registry is a prospective active surveillance registry that has recently reported on 585 patients with a 3.39 year median follow-up [29]. The rate of delayed intervention on active surveillance is 15%, with no difference in cancer-specific survival between those that elected primary vs. delayed intervention. The most common reasons for intervention are growth rate >0.5 cm/year or patient preference [30].
  • If treatment is elected, most patients are amenable to a robot-assisted partial nephrectomy. This has reduced morbidity over open partial nephrectomy and radical nephrectomy.
  • Other local therapies. percutaneous ablation offers a reasonable alternative to surgery and can be performed with cryoablation or radiofrequency ablation [31]. A biopsy should confirm malignancy before ablation. This approach has reduced morbidity relative to surgery, which may be particularly relevant to the patient with elevated surgical risk. LC rates may be slightly lower than that of a partial nephrectomy, which is relevant to a patient with a long life expectancy.
  • SABR. As discussed in the following sections, SABR is being increasingly considered.
Surgical candidates with a larger (>4 cm) renal mass generally undergo surgical resection with a partial or radical nephrectomy. A biopsy is less commonly performed given the higher rates of malignancy in this setting [32]. Ablative techniques [33], active surveillance [34], and SABR are alternatives to surgery that can be considered in a patient at elevated surgical risk.

3. Locally Advanced RCC

Renal cell carcinoma extending outside of the kidney without distant metastases is described as locally advanced. This may include involvement of the perinephric or renal sinus fat, renal vein or inferior vena cava (IVC), regional lymph nodes, or adjacent organs. In surgical candidates, locally advanced RCC is managed with surgical resection [35]. Adjuvant ICIs with pembrolizumab (anti-PD-1) for up to 1 year have been shown to reduce disease recurrence after nephrectomy by 37% for patients with locally advanced clear cell RCC [36][37]. Whether adjuvant pembrolizumab improves CSS has not yet been established.

4. Metastatic RCC

Metastatic RCC encompasses a wide range of disease aggressiveness that varies both in terms of rates of disease progression and disease burden. The International Metastatic Database Consortium (IMDC), externally validated by Heng et al. and now one of the most widely used risk stratification and prognostic models for mRCC, stratifies patients into three risk groupings—favorable (0 risk factors), intermediate (1–2 risk factors) and poor (3 or more risk factors)—based on the following risk factors:
○
Karnofsky performance < 80%;
○
Neutrophils > upper limit of normal;
○
Corrected calcium > upper limit of normal;
○
Platelets > upper limit of normal;
○
Hemoglobin < lower limit of normal;
○
<1 year from diagnosis to systemic therapy [38].
Management of mRCC involves multimodality management. Patients with a high burden of metastatic disease and multiple IMDC risk criteria are managed with upfront systemic therapy. Treatment of the kidney or metastatic lesions is not performed upfront unless symptomatic. Consolidative treatment of the renal primary or metastatic sites can be considered in the event of significant overall response or oligoprogression.
Newer systemic therapies in the form of targeted therapy or ICIs, either alone or in combination, have improved oncologic outcomes in mRCC. Unfortunately, eventual resistance to systemic therapy remains unavoidable [39]. In the context of this inevitable failure of systemic therapy, there remains a role for SABR as a local metastasis-directed therapy in selected mRCC patients. Patients with oligometastatic (OM) RCC are more frequently considered for upfront cytoreductive nephrectomy, active surveillance, and metastasis-directed therapy, especially to delay systemic therapy. In synchronous OM RCC, the decision to perform cytoreductive nephrectomy depends on the plan for metastatic disease—it is indicated when remaining metastatic disease will be managed with active surveillance or metastasis-directed therapy. For those patients in whom systemic therapy is intended, cytoreductive nephrectomy is reasonable when no other IMDC risk factors are present and the majority of disease burden is in the kidney [40][41]. Patients who can have complete control of metastatic lesions with metastasis-directed therapy are also considered for this approach. About half of patients who undergo cytoreductive nephrectomy with synchronous metastasis-directed therapy or active surveillance will remain off systemic therapy for at least one year [42][43]. Those with OM metachronous recurrences may remain off systemic therapy for much longer periods with metastasis-directed therapy [44].

References

  1. Siegel, R.L.; Miller, K.D.; Wagle, N.S.; Jemal, A. Cancer Statistics, 2023. CA Cancer J. Clin. 2023, 73, 17–48.
  2. Moch, H.; Amin, M.B.; Berney, D.M.; Compérat, E.M.; Gill, A.J.; Hartmann, A.; Menon, S.; Raspollini, M.R.; Rubin, M.A.; Srigley, J.R.; et al. The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. Eur. Urol. 2022, 82, 458–468.
  3. Cozad, S.C.; Smalley, S.R.; Austenfeld, M.; Noble, M.; Jennings, S.; Raymond, R. Transitional Cell Carcinoma of the Renal Pelvis or Ureter: Patterns of Failure. Urology 1995, 46, 796–800.
  4. Rabinovitch, R.A.; Zelefsky, M.J.; Gaynor, J.J.; Fuks, Z. Patterns of Failure Following Surgical Resection of Renal Cell Carcinoma: Implications for Adjuvant Local and Systemic Therapy. J. Clin. Oncol. 1994, 12, 206–212.
  5. Choueiri, T.K.; Powles, T.; Burotto, M.; Escudier, B.; Bourlon, M.T.; Zurawski, B.; Oyervides Juárez, V.M.; Hsieh, J.J.; Basso, U.; Shah, A.Y.; et al. Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N. Engl. J. Med. 2021, 384, 829–841.
  6. Motzer, R.; Alekseev, B.; Rha, S.-Y.; Porta, C.; Eto, M.; Powles, T.; Grünwald, V.; Hutson, T.E.; Kopyltsov, E.; Méndez-Vidal, M.J.; et al. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. N. Engl. J. Med. 2021, 384, 1289–1300.
  7. Motzer, R.J.; Penkov, K.; Haanen, J.; Rini, B.; Albiges, L.; Campbell, M.T.; Venugopal, B.; Kollmannsberger, C.; Negrier, S.; Uemura, M.; et al. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N. Engl. J. Med. 2019, 380, 1103–1115.
  8. Deschavanne, P.J.; Fertil, B. A Review of Human Cell Radiosensitivity in Vitro. Int. J. Radiat. Oncol. 1996, 34, 251–266.
  9. Walsh, L.; Stanfield, J.L.; Cho, L.C.; Chang, C.; Forster, K.; Kabbani, W.; Cadeddu, J.A.; Hsieh, J.-T.; Choy, H.; Timmerman, R.; et al. Efficacy of Ablative High-Dose-per-Fraction Radiation for Implanted Human Renal Cell Cancer in a Nude Mouse Model. Eur. Urol. 2006, 50, 795–800.
  10. Ning, S.; Trisler, K.; Wessels, B.W.; Knox, S.J. Radiobiologic Studies of Radioimmunotherapy and External Beam Radiotherapy in Vitro and in Vivo in Human Renal Cell Carcinoma Xenografts. Cancer 1997, 80, 2519–2528.
  11. Finkelstein, S.E.; Timmerman, R.; McBride, W.H.; Schaue, D.; Hoffe, S.E.; Mantz, C.A.; Wilson, G.D. The Confluence of Stereotactic Ablative Radiotherapy and Tumor Immunology. Clin. Dev. Immunol. 2011, 2011, 439752.
  12. DiBiase, S.J.; Valicenti, R.K.; Schultz, D.; Xie, Y.; Gomella, L.G.; Corn, B.W. Palliative Irradiation for Focally Symptomatic Metastatic Renal Cell Carcinoma: Support for Dose Escalation Based on a Biological Model. J. Urol. 1997, 158, 746–749.
  13. Wang, H.-H.; Cui, Y.-L.; Zaorsky, N.G.; Lan, J.; Deng, L.; Zeng, X.-L.; Wu, Z.-Q.; Tao, Z.; Guo, W.-H.; Wang, Q.-X.; et al. Mesenchymal Stem Cells Generate Pericytes to Promote Tumor Recurrence via Vasculogenesis after Stereotactic Body Radiation Therapy. Cancer Lett. 2016, 375, 349–359.
  14. Ali, M.; Mooi, J.; Lawrentschuk, N.; McKay, R.R.; Hannan, R.; Lo, S.S.; Hall, W.A.; Siva, S. The Role of Stereotactic Ablative Body Radiotherapy in Renal Cell Carcinoma. Eur. Urol. 2022, 82, 613–622.
  15. Chow, J.; Hoffend, N.C.; Abrams, S.I.; Schwaab, T.; Singh, A.K.; Muhitch, J.B. Radiation Induces Dynamic Changes to the T Cell Repertoire in Renal Cell Carcinoma Patients. Proc. Natl. Acad. Sci. USA 2020, 117, 23721–23729.
  16. Potters, L.; Kavanagh, B.; Galvin, J.M.; Hevezi, J.M.; Janjan, N.A.; Larson, D.A.; Mehta, M.P.; Ryu, S.; Steinberg, M.; Timmerman, R.; et al. American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) Practice Guideline for the Performance of Stereotactic Body Radiation Therapy. Int. J. Radiat. Oncol. Biol. Phys. 2010, 76, 326–332.
  17. Zelefsky, M.J.; Greco, C.; Motzer, R.; Magsanoc, J.M.; Pei, X.; Lovelock, M.; Mechalakos, J.; Zatcky, J.; Fuks, Z.; Yamada, Y. Tumor Control Outcomes after Hypofractionated and Single-Dose Stereotactic Image-Guided Intensity-Modulated Radiotherapy for Extracranial Metastases from Renal Cell Carcinoma. Int. J. Radiat. Oncol. 2012, 82, 1744–1748.
  18. Svedman, C.; Sandström, P.; Pisa, P.; Blomgren, H.; Lax, I.; Kälkner, K.-M.; Nilsson, S.; Wersäll, P. A Prospective Phase II Trial of Using Extracranial Stereotactic Radiotherapy in Primary and Metastatic Renal Cell Carcinoma. Acta Oncol. 2006, 45, 870–875.
  19. Wersäll, P.J.; Blomgren, H.; Lax, I.; Kälkner, K.-M.; Linder, C.; Lundell, G.; Nilsson, B.; Nilsson, S.; Näslund, I.; Pisa, P.; et al. Extracranial Stereotactic Radiotherapy for Primary and Metastatic Renal Cell Carcinoma. Radiother. Oncol. 2005, 77, 88–95.
  20. Wang, C.J.; Christie, A.; Lin, M.-H.; Jung, M.; Weix, D.; Huelsmann, L.; Kuhn, K.; Meyer, J.; Desai, N.; Kim, D.W.N.; et al. Safety and Efficacy of Stereotactic Ablative Radiation Therapy for Renal Cell Carcinoma Extracranial Metastases. Int. J. Radiat. Oncol. 2017, 98, 91–100.
  21. Guidelines Detail. Available online: https://www.nccn.org/guidelines/guidelines-detail (accessed on 1 June 2023).
  22. Capitanio, U.; Bensalah, K.; Bex, A.; Boorjian, S.A.; Bray, F.; Coleman, J.; Gore, J.L.; Sun, M.; Wood, C.; Russo, P. Epidemiology of Renal Cell Carcinoma. Eur. Urol. 2019, 75, 74–84.
  23. Campbell, S.C.; Clark, P.E.; Chang, S.S.; Karam, J.A.; Souter, L.; Uzzo, R.G. Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow-Up: AUA Guideline: Part I. J. Urol. 2021, 206, 199–208.
  24. Kim, J.H.; Li, S.; Khandwala, Y.; Chung, K.J.; Park, H.K.; Chung, B.I. Association of Prevalence of Benign Pathologic Findings after Partial Nephrectomy with Preoperative Imaging Patterns in the United States from 2007 to 2014. JAMA Surg. 2019, 154, 225–231.
  25. Richard, P.O.; Jewett, M.A.S.; Bhatt, J.R.; Kachura, J.R.; Evans, A.J.; Zlotta, A.R.; Hermanns, T.; Juvet, T.; Finelli, A. Renal Tumor Biopsy for Small Renal Masses: A Single-Center 13-Year Experience. Eur. Urol. 2015, 68, 1007–1013.
  26. Gorin, M.A.; Rowe, S.P.; Baras, A.S.; Solnes, L.B.; Ball, M.W.; Pierorazio, P.M.; Pavlovich, C.P.; Epstein, J.I.; Javadi, M.S.; Allaf, M.E. Prospective Evaluation of (99 m)Tc-Sestamibi SPECT/CT for the Diagnosis of Renal Oncocytomas and Hybrid Oncocytic/Chromophobe Tumors. Eur. Urol. 2016, 69, 413–416.
  27. Shuch, B.M.; Pantuck, A.J.; Bernhard, J.-C.; Morris, M.A.; Master, V.A.; Scott, A.M.; Van Praet, C.; Bailly, C.; Aksoy, T.; Merkx, R.; et al. Results from Phase 3 Study of 89Zr-DFO-Girentuximab for PET/CT Imaging of Clear Cell Renal Cell Carcinoma (ZIRCON). J. Clin. Oncol. 2023, 41, LBA602.
  28. Jewett, M.A.S.; Mattar, K.; Basiuk, J.; Morash, C.G.; Pautler, S.E.; Siemens, D.R.; Tanguay, S.; Rendon, R.A.; Gleave, M.E.; Drachenberg, D.E.; et al. Active Surveillance of Small Renal Masses: Progression Patterns of Early Stage Kidney Cancer. Eur. Urol. 2011, 60, 39–44.
  29. Alkhatib, K.Y.; Cheaib, J.; Singla, N.; Chang, P.; Wagner, A.A.; Pavlovich, C.P.; Mckiernan, J.M.; Guzzo, T.J.; Allaf, M.E.; Pierorazio, P.M. PD08-11 active surveillance versus primary intervention for clinical t1a kidney tumors: Twelve-year experience of the dissrm prospective comparative study. J. Urol. 2023, 209, e237.
  30. Gupta, M.; Alam, R.; Patel, H.D.; Semerjian, A.; Gorin, M.A.; Johnson, M.H.; Chang, P.; Wagner, A.A.; McKiernan, J.M.; Allaf, M.E.; et al. Use of Delayed Intervention for Small Renal Masses Initially Managed with Active Surveillance. Urol. Oncol. 2019, 37, 18–25.
  31. Leopold, Z.; Passarelli, R.; Mikhail, M.; Tabakin, A.; Chua, K.; Ennis, R.D.; Nosher, J.; Singer, E.A. Modern Management of Localized Renal Cell Carcinoma-Is Ablation Part of the Equation? J. Kidney Cancer VHL 2022, 9, 5–23.
  32. Frank, I.; Blute, M.L.; Cheville, J.C.; Lohse, C.M.; Weaver, A.L.; Zincke, H. Solid Renal Tumors: An Analysis of Pathological Features Related to Tumor Size. J. Urol. 2003, 170, 2217–2220.
  33. Yanagisawa, T.; Mori, K.; Kawada, T.; Motlagh, R.S.; Mostafaei, H.; Quhal, F.; Laukhtina, E.; Rajwa, P.; Aydh, A.; König, F.; et al. Differential Efficacy of Ablation Therapy versus Partial Nephrectomy between Clinical T1a and T1b Renal Tumors: A Systematic Review and Meta-Analysis. Urol. Oncol. Semin. Orig. Investig. 2022, 40, 315–330.
  34. Marzouk, K.; Tin, A.; Liu, N.; Sjoberg, D.; Hakimi, A.A.; Russo, P.; Coleman, J. The Natural History of Large Renal Masses Followed on Observation. Urol. Oncol. 2018, 36, 362.e17–362.e21.
  35. Margulis, V.; Freifeld, Y.; Pop, L.M.; Manna, S.; Kapur, P.; Pedrosa, I.; Christie, A.; Mohamad, O.; Mannala, S.; Singla, N.; et al. Neoadjuvant SABR for Renal Cell Carcinoma Inferior Vena Cava Tumor Thrombus-Safety Lead-in Results of a Phase 2 Trial. Int. J. Radiat. Oncol. Biol. Phys. 2021, 110, 1135–1142.
  36. Hannan, R.; McLaughlin, M.F.; Pop, L.M.; Pedrosa, I.; Kapur, P.; Garant, A.; Ahn, C.; Christie, A.; Zhu, J.; Wang, T.; et al. Phase 2 Trial of Stereotactic Ablative Radiotherapy for Patients with Primary Renal Cancer. Eur. Urol. 2023, 84, 275–286.
  37. Siva, S.; Bressel, M.; Sidhom, M.; Sridharan, S.; Vanneste, B.; Davey, R.; Ruben, J.; Foroudi, F.; Higgs, B.G.; Lin, C.; et al. TROG 15.03/ANZUP International Multicenter Phase II Trial of Focal Ablative STereotactic RAdiotherapy for Cancers of the Kidney (FASTRACK II). Int. J. Radiat. Oncol. Biol. Phys. 2023, 117, S3.
  38. Heng, D.Y.C.; Xie, W.; Regan, M.M.; Harshman, L.C.; Bjarnason, G.A.; Vaishampayan, U.N.; Mackenzie, M.; Wood, L.; Donskov, F.; Tan, M.-H.; et al. External Validation and Comparison with Other Models of the International Metastatic Renal-Cell Carcinoma Database Consortium Prognostic Model: A Population-Based Study. Lancet Oncol. 2013, 14, 141–148.
  39. Liu, Y.; Zhang, Z.; Han, H.; Guo, S.; Liu, Z.; Liu, M.; Zhou, F.; Dong, P.; He, L. Survival After Combining Stereotactic Body Radiation Therapy and Tyrosine Kinase Inhibitors in Patients with Metastatic Renal Cell Carcinoma. Front. Oncol. 2021, 11, 607595.
  40. Rathmell, W.K.; Rumble, R.B.; Van Veldhuizen, P.J.; Al-Ahmadie, H.; Emamekhoo, H.; Hauke, R.J.; Louie, A.V.; Milowsky, M.I.; Molina, A.M.; Rose, T.L.; et al. Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline. J. Clin. Oncol. 2022, 40, 2957–2995.
  41. Dason, S.; Lacuna, K.; Hannan, R.; Singer, E.A.; Runcie, K. State of the Art: Multidisciplinary Management of Oligometastatic Renal Cell Carcinoma. Am. Soc. Clin. Oncol. Educ. Book 2023, 43, e390038.
  42. Andrews, J.R.; Lohse, C.M.; Boorjian, S.A.; Leibovich, B.C.; Thompson, H.; Costello, B.A.; Bhindi, B. Outcomes Following Cytoreductive Nephrectomy without Immediate Postoperative Systemic Therapy for Patients with Synchronous Metastatic Renal Cell Carcinoma. Urol. Oncol. 2022, 40, 166.e1–166.e8.
  43. Rini, B.I.; Dorff, T.B.; Elson, P.; Rodriguez, C.S.; Shepard, D.; Wood, L.; Humbert, J.; Pyle, L.; Wong, Y.-N.; Finke, J.H.; et al. Active Surveillance in Metastatic Renal-Cell Carcinoma: A Prospective, Phase 2 Trial. Lancet Oncol. 2016, 17, 1317–1324.
  44. Lyon, T.D.; Thompson, R.H.; Shah, P.H.; Lohse, C.M.; Boorjian, S.A.; Costello, B.A.; Cheville, J.C.; Leibovich, B.C. Complete Surgical Metastasectomy of Renal Cell Carcinoma in the Post-Cytokine Era. J. Urol. 2020, 203, 275–282.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Oncology
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Rohit K. Raj
,
Rituraj Upadhyay
,
Shang-Jui Wang
,
Eric A. Singer
,
Shawn Dason
View Times: 139
Revisions: 2 times (View History)
Update Date: 05 Dec 2023
Table of Contents
    1000/1000
    Hot Most Recent
    Video Production Service
    Feedback